Cargando…

The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects

Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto(®) or Stiolto(®) is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the l...

Descripción completa

Detalles Bibliográficos
Autores principales: Derom, Eric, Brusselle, Guy G., Joos, Guy F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475840/
https://www.ncbi.nlm.nih.gov/pubmed/31002020
http://dx.doi.org/10.1177/1753466619843426
_version_ 1783412815328968704
author Derom, Eric
Brusselle, Guy G.
Joos, Guy F.
author_facet Derom, Eric
Brusselle, Guy G.
Joos, Guy F.
author_sort Derom, Eric
collection PubMed
description Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto(®) or Stiolto(®) is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the long-acting β2-adrenoceptor agonist olodaterol (OLO), formulated in the Respimat(®) Soft Mist™ inhaler. A total of 13 large, multicentre studies of up to 52 weeks’ duration have documented its efficacy in more than 15,000 patients with COPD. TIO/OLO 5/5 µg FDC significantly increases pulmonary function compared with placebo and its respective constituent mono-components TIO 5 µg and OLO 5 µg. TIO/OLO 5/5 µg also results in statistically and clinically significant improvements in patient-reported outcomes, such as dyspnoea, use of rescue medication, and health status. Addition of OLO 5 µg to TIO 5 µg reduces the rate of moderate-to-severe exacerbations by approximately 10%. Compared with placebo and TIO 5 µg, TIO/OLO 5/5 µg significantly improves exercise capacity (e.g. endurance time) and physical activity, the latter increase being reached by a unique combination behavioural modification intervention, dual bronchodilatation and exercise training. Overall, the likelihood for patients to experience a clinically significant benefit is higher with TIO/OLO 5/5 µg than with its constituent mono-components, which usually yield smaller improvements which do not always reach statistical significance, compared with baseline or placebo. This supports the early introduction of TIO/OLO 5/5 µg in the management of patients with symptomatic COPD.
format Online
Article
Text
id pubmed-6475840
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-64758402019-04-29 The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects Derom, Eric Brusselle, Guy G. Joos, Guy F. Ther Adv Respir Dis Review Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto(®) or Stiolto(®) is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the long-acting β2-adrenoceptor agonist olodaterol (OLO), formulated in the Respimat(®) Soft Mist™ inhaler. A total of 13 large, multicentre studies of up to 52 weeks’ duration have documented its efficacy in more than 15,000 patients with COPD. TIO/OLO 5/5 µg FDC significantly increases pulmonary function compared with placebo and its respective constituent mono-components TIO 5 µg and OLO 5 µg. TIO/OLO 5/5 µg also results in statistically and clinically significant improvements in patient-reported outcomes, such as dyspnoea, use of rescue medication, and health status. Addition of OLO 5 µg to TIO 5 µg reduces the rate of moderate-to-severe exacerbations by approximately 10%. Compared with placebo and TIO 5 µg, TIO/OLO 5/5 µg significantly improves exercise capacity (e.g. endurance time) and physical activity, the latter increase being reached by a unique combination behavioural modification intervention, dual bronchodilatation and exercise training. Overall, the likelihood for patients to experience a clinically significant benefit is higher with TIO/OLO 5/5 µg than with its constituent mono-components, which usually yield smaller improvements which do not always reach statistical significance, compared with baseline or placebo. This supports the early introduction of TIO/OLO 5/5 µg in the management of patients with symptomatic COPD. SAGE Publications 2019-04-19 /pmc/articles/PMC6475840/ /pubmed/31002020 http://dx.doi.org/10.1177/1753466619843426 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Derom, Eric
Brusselle, Guy G.
Joos, Guy F.
The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
title The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
title_full The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
title_fullStr The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
title_full_unstemmed The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
title_short The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
title_sort once-daily fixed-dose combination of olodaterol and tiotropium in the management of copd: current evidence and future prospects
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475840/
https://www.ncbi.nlm.nih.gov/pubmed/31002020
http://dx.doi.org/10.1177/1753466619843426
work_keys_str_mv AT deromeric theoncedailyfixeddosecombinationofolodaterolandtiotropiuminthemanagementofcopdcurrentevidenceandfutureprospects
AT brusselleguyg theoncedailyfixeddosecombinationofolodaterolandtiotropiuminthemanagementofcopdcurrentevidenceandfutureprospects
AT joosguyf theoncedailyfixeddosecombinationofolodaterolandtiotropiuminthemanagementofcopdcurrentevidenceandfutureprospects
AT deromeric oncedailyfixeddosecombinationofolodaterolandtiotropiuminthemanagementofcopdcurrentevidenceandfutureprospects
AT brusselleguyg oncedailyfixeddosecombinationofolodaterolandtiotropiuminthemanagementofcopdcurrentevidenceandfutureprospects
AT joosguyf oncedailyfixeddosecombinationofolodaterolandtiotropiuminthemanagementofcopdcurrentevidenceandfutureprospects